Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
Epistemonikos ID: cf5c458eadd15c495b5dd9d77f75c9b99d2e8441
First added on: May 21, 2024